One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
MiNK Therapeutics, Inc.
INKT · NCM · Healthcare · Biotechnology
Current price
$10.80
52-week range
$8.48 - $16.93
Market cap
$55.11M
Balance sheet
Healthy
-5.14x Concerning
Net cash $8.81M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
0 Risks
0 rewards · 0 risks
Highlights are unavailable right now.
What this company does
MiNK Therapeutics, Inc.
MiNK Therapeutics is developing special cell therapies, like agenT-797, to help the body fight cancer and other immune system problems. Their main money comes from potential future sales of these experimental treatments and partnerships with other companies working on similar medical advancements. This matters because if their therapies prove successful in trials, they could offer new hope to patients with difficult-to-treat diseases.
How the company got here
MiNK Therapeutics, Inc. started as AgenTus Therapeutics, Inc. in 2017, aiming to develop new treatments for serious diseases. The company officially changed its name to MiNK Therapeutics in June 2021, signaling a new phase in its journey. Its focus is on creating innovative cell therapies, which involve using a patient's own or donor's cells to fight illness. This pivot towards specialized cell therapies is a key part of its evolution in the competitive biotechnology landscape.
What it actually does
MiNK Therapeutics is a biopharmaceutical company working on developing a type of treatment called 'allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies.' Think of it like this: instead of creating a unique medicine for each patient, they are developing a ready-to-use therapy derived from healthy donor cells. These specialized cells are designed to help the body's immune system fight diseases, particularly cancer and other conditions where the immune system is involved.
Allogeneic iNKT Cell Therapies
This is the core of MiNK Therapeutics' business. They are developing treatments using a specific type of immune cell called an invariant natural killer T (iNKT) cell. The 'allogeneic, off-the-shelf' part means these therapies are made from healthy donor cells and can be used for multiple patients without needing to be custom-made for each one, much like how a blood bank has blood ready for transfusions. Their main product in this area, agenT-797, is being tested in clinical trials for various cancers and a severe lung condition called viral acute respiratory distress syndrome (ARDS).
CAR-iNKT Programs
MiNK Therapeutics is also exploring advanced versions of their cell therapy technology. This includes developing 'CAR-iNKT' programs, which are engineered iNKT cells designed to target specific markers on diseased cells, like cancer cells. For example, MiNK-215 is being developed to target solid tumors by arming the iNKT cells with a specific protein (IL-15) and directing them to attack a marker called FAP. Another program, MiNK-413, is being designed to target autoimmune diseases by focusing on a different marker (BCMA) and also using the IL-15 enhancement.
What management is betting on now
Management is focused on advancing their pipeline of iNKT cell therapies through clinical trials. A key priority is testing agenT-797 in combination with other cancer treatments to see if it can improve outcomes for patients with advanced cancers. They are also investing in developing their next-generation therapies, like the CAR-iNKT programs, which represent a more targeted approach to treating difficult diseases. Success in these trials is crucial for the company's future growth and ability to bring these innovative treatments to patients.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-3.13M
Diluted EPS
-0.62
Operating cash flow
$-2.08M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.74M
Diluted EPS
-0.57
Operating cash flow
$-1.73M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.60M
Diluted EPS
-0.52
Operating cash flow
$-2.07M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.89M
Diluted EPS
-0.65
Operating cash flow
$-941.35K
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-4.24M
Diluted EPS
-1.06
Operating cash flow
$-1.57M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.77M
Diluted EPS
-0.70
Operating cash flow
$-1.34M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.46M
Diluted EPS
-2.63
Operating cash flow
$-1.73M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.81M
Diluted EPS
-0.05
Operating cash flow
$-2.99M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $10.80
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $8.8M - more cash than debt. Interest coverage -5.1x.
Net debt
$-8.81M
Interest coverage
-5.14x
MiNK Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
INKT
BASELINE
MiNK Therapeutics, Inc.
Total debt $0.00 Interest coverage -5.14x This is the baseline the peer rows are being compared against.
Total debt $834.00K Interest coverage -24.18x Neither company has much profit cushion over interest right now.
Total debt $28.74M Interest coverage -61.11x Neither company has much profit cushion over interest right now.
Total debt $32.41M Interest coverage -12.14x Neither company has much profit cushion over interest right now.
Total debt $643.00K Interest coverage -141.45x Neither company has much profit cushion over interest right now.
What you should know
The case for and against INKT
0 Rewards
0 Risks
Rewards
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-4.93x
P/B
-3.92x
P/S
—
EV/EBITDA
-3.84x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
—
ROA
-123.8%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
1.23x
Quick ratio
1.16x
Total debt
$0.00
Total cash
$8.81M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-2.39
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-6.83M
Free CF TTM
$-9.63M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—